127 related articles for article (PubMed ID: 15745762)
1. The Low-pressure Glaucoma Treatment Study (LoGTS) study design and baseline characteristics of enrolled patients.
Krupin T; Liebmann JM; Greenfield DS; Rosenberg LF; Ritch R; Yang JW;
Ophthalmology; 2005 Mar; 112(3):376-85. PubMed ID: 15745762
[TBL] [Abstract][Full Text] [Related]
2. Randomised controlled trial comparing the effect of brimonidine and timolol on visual field loss after acute primary angle closure.
Aung T; Oen FT; Wong HT; Chan YH; Khoo BK; Liu YP; Ho CL; See J; Thean LH; Viswanathan AC; Seah SK; Chew PT
Br J Ophthalmol; 2004 Jan; 88(1):88-94. PubMed ID: 14693782
[TBL] [Abstract][Full Text] [Related]
3. The Association between Medication Adherence and Visual Field Progression in the Collaborative Initial Glaucoma Treatment Study.
Newman-Casey PA; Niziol LM; Gillespie BW; Janz NK; Lichter PR; Musch DC
Ophthalmology; 2020 Apr; 127(4):477-483. PubMed ID: 31932093
[TBL] [Abstract][Full Text] [Related]
4. Effect of brimonidine on retinal vascular autoregulation and short-term visual function in normal tension glaucoma.
Feke GT; Bex PJ; Taylor CP; Rhee DJ; Turalba AV; Chen TC; Wand M; Pasquale LR
Am J Ophthalmol; 2014 Jul; 158(1):105-112.e1. PubMed ID: 24709811
[TBL] [Abstract][Full Text] [Related]
5. The association between glaucoma treatment adherence with disease progression and loss to follow-up.
Oltramari L; Mansberger SL; Souza JMP; de Souza LB; de Azevedo SFM; Abe RY
Sci Rep; 2024 Jan; 14(1):2195. PubMed ID: 38273029
[TBL] [Abstract][Full Text] [Related]
6. Mapping vision loss of patients in a glaucoma backlog following the COVID-19 pandemic: a real-world analysis using the Glauc-Strat-Fast risk stratification tool.
Sharma O; Jones L; Sii F; Whittaker J; Dulku S; Lee G; Kirwan J; Sharma T; Shah P
Eye (Lond); 2024 Apr; 38(5):1005-1011. PubMed ID: 37980397
[TBL] [Abstract][Full Text] [Related]
7. Effects of socioeconomic status on baseline values and outcomes at 24 months in the Treatment of Advanced Glaucoma Study randomised controlled Trial.
King AJ; Hudson J; Azuara-Blanco A; Kirwan JF; Goyal S; Lim KS; Maclennan G;
Br J Ophthalmol; 2024 Jan; 108(2):203-210. PubMed ID: 36596663
[TBL] [Abstract][Full Text] [Related]
8. One Year of Glaucoma Research in Review: 2012 to 2013.
Kim C; Demetriades AM; Radcliffe NM
Asia Pac J Ophthalmol (Phila); 2014; 3(1):48-55. PubMed ID: 25177529
[TBL] [Abstract][Full Text] [Related]
9. Phenotypic Description of the Spanish Multicentre Genetic Glaucoma Group Cohort.
Milla E; Gamundi MJ; Duch S; Rios J; Carballo M; Study Group E
J Ophthalmol; 2017; 2017():1907454. PubMed ID: 29082038
[TBL] [Abstract][Full Text] [Related]
10. A randomized trial of brimonidine versus timolol in preserving visual function: results from the Low-Pressure Glaucoma Treatment Study.
Krupin T; Liebmann JM; Greenfield DS; Ritch R; Gardiner S;
Am J Ophthalmol; 2011 Apr; 151(4):671-81. PubMed ID: 21257146
[TBL] [Abstract][Full Text] [Related]
11. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Collaborative Normal-Tension Glaucoma Study Group.
Am J Ophthalmol; 1998 Oct; 126(4):498-505. PubMed ID: 9780094
[TBL] [Abstract][Full Text] [Related]
12. Neuroprotection for treatment of glaucoma in adults.
Sena DF; Lindsley K
Cochrane Database Syst Rev; 2013 Feb; 2(2):CD006539. PubMed ID: 23450569
[TBL] [Abstract][Full Text] [Related]
13. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Collaborative Normal-Tension Glaucoma Study Group.
Am J Ophthalmol; 1998 Oct; 126(4):487-97. PubMed ID: 9780093
[TBL] [Abstract][Full Text] [Related]
14. Risk factors for visual field progression in the low-pressure glaucoma treatment study.
De Moraes CG; Liebmann JM; Greenfield DS; Gardiner SK; Ritch R; Krupin T;
Am J Ophthalmol; 2012 Oct; 154(4):702-11. PubMed ID: 22835512
[TBL] [Abstract][Full Text] [Related]
15. New directions in the treatment of normal tension glaucoma.
Song BJ; Caprioli J
Indian J Ophthalmol; 2014 May; 62(5):529-37. PubMed ID: 24881596
[TBL] [Abstract][Full Text] [Related]
16. Neuroprotection for treatment of glaucoma in adults.
Sena DF; Lindsley K
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD006539. PubMed ID: 28122126
[TBL] [Abstract][Full Text] [Related]
17. Visual field and intraocular pressure asymmetry in the low-pressure glaucoma treatment study.
Greenfield DS; Liebmann JM; Ritch R; Krupin T;
Ophthalmology; 2007 Mar; 114(3):460-5. PubMed ID: 17141318
[TBL] [Abstract][Full Text] [Related]
18. Risk factors for optic disc hemorrhage in the low-pressure glaucoma treatment study.
Furlanetto RL; De Moraes CG; Teng CC; Liebmann JM; Greenfield DS; Gardiner SK; Ritch R; Krupin T;
Am J Ophthalmol; 2014 May; 157(5):945-52. PubMed ID: 24513094
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of open-angle glaucoma in Australia. The Blue Mountains Eye Study.
Mitchell P; Smith W; Attebo K; Healey PR
Ophthalmology; 1996 Oct; 103(10):1661-9. PubMed ID: 8874440
[TBL] [Abstract][Full Text] [Related]
20. Herpetic Eye Disease Study. A controlled trial of oral acyclovir for herpes simplex stromal keratitis.
Barron BA; Gee L; Hauck WW; Kurinij N; Dawson CR; Jones DB; Wilhelmus KR; Kaufman HE; Sugar J; Hyndiuk RA
Ophthalmology; 1994 Dec; 101(12):1871-82. PubMed ID: 7997323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
